Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Inhibikase Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/17/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/29/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 03/22/2023 |
8-K
| Investor presentation |
| 03/13/2023 |
8-K
| Other Events Interactive Data |
| 03/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/26/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Secu...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Form of Pre-Funded Warrant",
"Form of Private Common Warrant",
"Form of PIPE Pre-Funded Warrant",
"Form of PIPE Common Warrant",
"Form of Placement Agent Warrant",
"Opinion of McDermott Will & Emery LLP",
"Securities Purchase Agreement, (Registered Direct)",
"Securities Purchase Agreement, (PIPE)",
"Registration Rights Agreement, (PIPE)",
"Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced At a Premium to Market Under Nasdaq Rules BOSTON and ATLANTA, January 25, 2023 — Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease , Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has entered into definitive agreements for the issuance and sale of 6,744,187 of its shares of common stock at a purchase price of $0.86 per share in a registered direct offering. In a concurrent private placement, Inhibikase has also agreed to issue and sell 4,883,721 of its shares of common stock , at the same purchase price as i..." |
|
| 01/25/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 01/24/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 11/17/2022 |
8-K
| Quarterly results |
| 11/07/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/16/2022 |
8-K
| Investor presentation |
| 09/01/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
8-K
| Quarterly results |
| 07/28/2022 |
8-K
| Quarterly results |
| 06/29/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
8-K
| Quarterly results |
| 04/21/2022 |
8-K
| Investor presentation |
| 03/24/2022 |
8-K
| Investor presentation |
| 03/21/2022 |
8-K/A
| Quarterly results |
| 03/08/2022 |
8-K
| Quarterly results |
| 01/20/2022 |
8-K
| Investor presentation |
| 10/19/2021 |
8-K
| Quarterly results |
| 09/08/2021 |
8-K
| Quarterly results |
| 08/17/2021 |
8-K
| Investor presentation |
| 06/28/2021 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 06/21/2021 |
8-K
| Quarterly results |
| 06/16/2021 |
8-K
| Quarterly results |
| 06/01/2021 |
8-K
| Investor presentation |
| 02/08/2021 |
8-K
| Quarterly results |
| 12/29/2020 |
8-K
| Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Even...|
Docs:
|
"Amended and Restated Certificate of Incorporation of Inhibikase Therapeutics, Inc",
"Amended and Restated Bylaws of Inhibikase Therapeutics, Inc",
"About Inhibikase Inhibikase is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's Disease and related disorders that arise inside and outside of the brain. Inhibikase is headquartered in Atlanta, Georgia with additional offices in Boston, Massachusetts. Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements, including statements regarding the closing of the initial public offering and the pr...",
"About Inhibikase Inhibikase is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's Disease and related disorders that arise inside and outside of the brain. Inhibikase is headquartered in Atlanta, Georgia with additional offices in Boston, Massachusetts. Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements, including statements regarding the closing of the initial public offering and the pr..." |
|
|
|